Disc Medicine's Phase 3 Win Clears the Main Scientific Hurdle for Bitopertin

Disc Medicine has produced the evidence that bitopertin lacked when the Food and Drug Administration rejected its first application in February. In the 183-patient Phase 3 APOLLO trial, the once-daily drug met both primary endpoints and every secondary endpoint in adults and adolescents with erythropoietic protoporphyria, or EPP.

EPP causes painful reactions to light because protoporphyrin IX, known as PPIX, accumulates in the body. Disc reported that bitopertin lowered whole-blood metal-free PPIX by 41.4% relative to placebo and increased pain-free light exposure by an average of 12.2 hours during the sixth month of treatment. Patients also experienced 71% fewer painful light-induced reactions, according to the company.

Those results matter because the FDA's February complete response letter did not dispute that bitopertin lowered PPIX. The agency said earlier studies had not established that the biomarker change translated into meaningful clinical benefit. APOLLO directly measured both the biomarker and patients' ability to tolerate light, which is the connection regulators had asked to see.

The safety result was broadly manageable but not trivial. Dizziness occurred in 50% of patients receiving bitopertin, versus 11% on placebo. Disc said those events were mild or moderate and caused no treatment discontinuations. The topline disclosure is encouraging, but a full regulatory review will examine the complete safety database, protocol details and consistency across subgroups.

Disc plans to resubmit its application by the end of 2026 and has said an FDA decision could arrive by mid-2027. The company reported $718 million of cash and investments at the end of June, which it expects to fund operations into 2029. It also priced a $450 million public offering after the trial readout, strengthening the balance sheet while diluting existing shareholders.

The remaining risk has shifted. Before APOLLO, investors had to question whether bitopertin could show clinical benefit. Now the central questions are whether the FDA accepts the trial as a sufficient response, how it interprets the dizziness rate and whether launch preparation can turn a positive decision into commercial uptake. The Phase 3 result is a major de-risking event, but approval is still a regulatory judgment, not an automatic consequence of statistical success.